Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Adeptus Biotechnologies Corp. (ADPT) PT Raised to $11 at Morgan Stanley
August 6, 2025 7:56 AM EDTMorgan Stanley analyst Tejas Savant raised the price target on Adeptus Biotechnologies Corp. (NASDAQ: ADPT) to $11.00 (from $9.00) while maintaining a Equalweight rating.
The analyst comments "Another solid beat/raise as clonoSEQ volume/ASP momentum continues on payor traction, community/EMR uptake; MRD EBITDA... More
